VP & GM, Global Biologics
September 25, 2013
Growth continues in devices for insulin delivery, driven by continuing diagnosis and increased use of devices such as pens.
A key trend is an increased need for delivery systems capable of containing and delivering injectable doses of greater than 1mL, either in a single-dose rapid shot, or slowly over a longer period of time. This trend is driven by the challenges of next-generation biologics, including increased concentrations and higher viscosities. There is also a trend toward reduced dosing frequency, which may help improve patient comfort and compliance.
West offers a variety of self-injection technologies, including the SelfDoseTM, SmartDose® and ConfiDose® injector platform technologies. For more information click here.
West seeks partners for its injector technology platforms. These platforms are intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.